We are live on ! Find out more
IMVT icon

Immunovant
IMVT

24 hedge funds and large institutions have $176M invested in Immunovant in 2019 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

382% more capital invested

Capital invested by funds: $36.6M → $176M (+$140M)

91% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 11

71% more funds holding

Funds holding: 14 → 24 (+10)

5.02% less ownership

Funds ownership: 25.6% → 20.58% (-5%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
24
Holders Change
+10
Holders Change %
+71.43%
% of All Funds
0.47%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
21
Increased
–
Reduced
2
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
RI
RTW Investments
New York
+$49.6M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$11.4M
3
BI
BVF Inc
California
+$11.2M
4
GTC
Ghost Tree Capital
New York
+$8.96M
5
DCM
Driehaus Capital Management
Illinois
+$6.96M

Top Sellers

1
6CM
683 Capital Management
New York
-$8.81M
2
GL
Governors Lane
New York
-$8.21M
3
DKCM
Davidson Kempner Capital Management
New York
-$5.13M
4
BFM
Boothbay Fund Management
New York
-$3.94M
5
JGC
J. Goldman & Co
New York
-$3.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$66M +$49.6M +4,426,106 New
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$16.2M +$11.4M +1,020,000 New
BI
3
BVF Inc
California
$15.8M +$11.2M +999,996 New
GTC
4
Ghost Tree Capital
New York
$12.7M +$8.96M +800,000 New
DCM
5
Driehaus Capital Management
Illinois
$9.85M +$6.96M +621,505 New
BlackRock
6
BlackRock
New York
$9.52M +$6.72M +599,867 New
IC
7
Ikarian Capital
Texas
$8M +$5.65M +504,117 New
AC
8
Athanor Capital
New York
$7.93M +$5.6M +500,000 New
PC
9
Polar Capital
United Kingdom
$6.25M +$4.41M +393,750 New
SCM
10
Sio Capital Management
New York
$5.48M +$6.89M +615,400 New
WP
11
Woodline Partners
California
$4.32M +$3.05M +272,539 New
PM
12
Prosight Management
Texas
$3.57M +$2.52M +224,702 New
GPCM
13
Granite Point Capital Management
Massachusetts
$3.49M +$2.46M +220,000 New
MP
14
Mangrove Partners
Connecticut
$1.59M – – –
SSA
15
Schonfeld Strategic Advisors
New York
$1.35M +$952K +85,000 New
BFM
16
Boothbay Fund Management
New York
$1.34M -$3.94M -351,601 -81%
EP
17
Eversept Partners
New York
$1.22M +$861K +76,866 New
Northern Trust
18
Northern Trust
Illinois
$374K +$264K +23,574 New
ECM
19
ExodusPoint Capital Management
New York
$346K +$244K +21,800 New
SFM
20
Sphera Funds Management
Israel
$317K +$224K +20,000 New
PC
21
PA Capital
Virginia
$220K +$155K +13,871 New
6CM
22
683 Capital Management
New York
$213K -$8.81M -786,600 -98%
UBS Group
23
UBS Group
Switzerland
$17K +$12.1K +1,076 New
Morgan Stanley
24
Morgan Stanley
New York
$16K +$11.2K +1,000 New
GL
25
Governors Lane
New York
– -$8.21M -828,004 Closed
1
2

IMVT Hedge Fund Activity: Q4 2019 in Review

24 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q4 2019, worth a combined $176M — up 382% from $36.6M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new IMVT positions and 11 closed out — a net gain of 10 holders — while 0 added to existing stakes and 2 trimmed.

The largest buyer was RTW Investments, opening a new position worth an estimated $49.6M. The largest seller was 683 Capital Management, cutting an estimated $8.81M.

  • 24 institutional investors held Immunovant (IMVT) as of Q4 2019, up from 14 in Q3 2019.
  • Funds reported $176M of Immunovant stock for Q4 2019, up 382% quarter-over-quarter.
  • 21 funds opened new Immunovant positions in Q4 2019 and 11 closed out, a net change of +10 holders.
  • The largest Immunovant buyer in Q4 2019 was RTW Investments, an estimated $49.6M added.
  • The largest Immunovant seller in Q4 2019 was 683 Capital Management, an estimated $8.81M sold.

Based on aggregated 13F filings for Q4 2019.